Search

Background: Autologous stem cell transplantation (ASCT) is the standard treatment strategy for refractory or relapsed classical Hodgkin lymphoma (R/R cHL). However, a single transplantation is insufficient to cure the disease because of unfavorable risk factors. Herein, we evaluated the outcomes of single or tandem ASCT in patients with R/R cHL, especially in high‐risk patients. Methods: We retrospectively analyzed R/R cHL patients who underwent single or tandem ASCT between April 2000 and June 2021 at the Beijing Cancer Hospital and Peking University International Hospital. Results: A total of 134 patients were enrolled. Patients were allocated to a favorable‐risk group (group A, n = 33), an unfavorable‐risk group (group B, n = 81) that underwent single ASCT, and an unfavorable‐risk group that underwent tandem ASCT (group C, n = 20). The median follow‐up time was 99 months (range, 91–107 months), and no treatment‐related deaths occurred after single or tandem ASCT. However, 27 patients (2 in group C) died during the follow‐up period. The groups A, B, and C had 5‐year progression‐free survival (PFS) rates of 77.05%, 45%, and 74.67%, respectively (p = 0.0014), and 5‐year overall survival (OS) rates of 89.85%, 76.06%, and 95%, respectively (p = 0.18). Neither the median PFS rates of groups A and C nor the OS rates of all groups were reached. Conclusions: Our study discusses the advantages of tandem transplantation for high‐risk patients with R/R cHL. [ABSTRACT FROM AUTHOR]

Camrelizumab (a humanized high‐affinity IgG4 mAb against programmed death‐l) showed potent antitumor activity, well tolerance and controllable safety in patients with relapsed or refractory classical Hodgkin lymphoma (r/r cHL), based on the primary analysis of a Phase 2 study. Here, we present the extended follow‐up outcomes. Seventy‐five patients who had failed to achieve a remission or experienced progression after autologous stem cell transplantation or had received at least two lines of systemic chemotherapies were enrolled to receive camrelizumab 200 mg every 2 weeks. With a median follow‐up of 36.2 months (range, 7.2‐38.1), objective response rate per independent central review was 76.0% (95% confidence interval [CI], 64.7‐85.1). Among the 57 responders, 31 (54.4%) had ongoing responses. Median duration of response was 31.7 months (95% CI, 16.7‐not reached). Median progression‐free survival was 22.5 months (95% CI, 14.7‐not reached). Thirty‐six‐month overall survival rate was 82.7% (95% CI, 72.0‐89.5). Reactive capillary endothelial proliferation (RCEP) occurred in 97.3% of patients (73/75), but all RCEP were Grade 1 or 2 in severity and 67.1% of these patients (49/73) achieved complete resolution. Occurrence of new RCEP lesions was rare (8/42 [19.0%] at 12 months; 2/32 [6.3%] at 24 months). No treatment‐related deaths occurred, and no new toxicities were reported. With extended follow‐up, camrelizumab monotherapy continues to provide a robust and durable response, long survival and manageable safety in r/r cHL patients. What's new? In an earlier phase 2 study, the PD‐1 inhibitor camrelizumab showed strong antitumor activity and a good safety profile in patients with relapsed or refractory classical Hodgkin's lymphoma (r/r cHL). Here, the authors report the results of a 3‐year follow up study. In the study, patients received 200 mg camrelizumab every two weeks. Of the 75 patients enrolled, 57 (76%) responded to the therapy, and 31 had ongoing responses. There were no treatment‐related deaths or new toxicities. Overall survival at 36 months was 82.7%. Camrelizumab appears to have a durable response in patients with r/r cHL. [ABSTRACT FROM AUTHOR]